Revive Therapeutics (RVVTF) Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
VERU Inc. (VERU) $24. High Risk, Minimal Reward?
Pre-FDA Approval Play. The Shares Are Now in the Hands of Fast Money Traders.
You Can't Kiss all the...
Adding Alkaline Water (WTER) to 2022 Beverage Watch List at $0.46, More Names Coming.
The Alkaline Water Company (WTER). Identifies $15 Million in Cost Savings and Margin Enhancements.
With nearly $200 million...
Private Investor Meetup with Football Star Tim Wright.
Saturday August 6th, Delray Beach
Exclusive cocktail hour with Super Bowl Champion and Dome Audio Founder Tim Wright.
FDA Issues Final ‘Enforcement Discretion’ Guidance on NAC.
NAC Crosses Major Hurdle With FDA. Is Bucillamine Next.
Josh Long | Aug 01, 2022
"Industry, and...
DCS (DCSX) and US Cellular Jointly Provided 4G LTE Wireless Upgrades for the Duplin...
San Diego, California--(Newsfile Corp. - July 25, 2022) - Direct Communication Solutions, Inc. (OTCQX: DCSX) (CSE: DCSI) (FSE: 7QU) a leading provider of information...
Chula Vista Scamster Gets Pinched
Great detective work by the SEC on this. If you ever wonder how/why your stock or stock you're following drops from $1.00...
Car Loan Crisis Ahead?
https://youtu.be/J5j4TJgdXtk
Revive Therapeutics (RVVTF) Enters the Danger Zone.
What Danger You Ask?
Danger #1, the FDA doesn't like the data, and you own the stock.
Adding Provention Bio (PRVB) $4.60 to 2022 Biotech Watch List.
This is in our 'Stocks we Hope to Double' Watch List.
LIVE QUOTE